<DOC>
	<DOC>NCT01540461</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of Brivanib in Chinese subjects with Advanced Hepatocellular Carcinoma (HCC).</brief_summary>
	<brief_title>Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Subjects with: Confirmed Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC) Not having received prior systemic treatment for advanced HCC Normal or moderately impaired liver function (ChildPugh Class A or B (CP total score of â‰¤ 7)) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Subjects with: Brain metastasis or evidence of leptomeningeal disease History of impaired brain function (encephalopathy) or active heart disease Unmanageable fluid in the abdomen (ascites) Bleeding esophageal or gastric varices within 2 months prior to inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HCC</keyword>
</DOC>